1. Alkermes will present at Goldman Sachs' healthcare conference in June 2025. 2. The webcast will be available for 14 days post-presentation. 3. Alkermes focuses on innovative neuroscience medicines and has a diverse pipeline.
The announcement is routine; investor response may vary but lacks immediate impact.
While important for visibility, it doesn't present new information or outcomes.
Future presentations could influence perceptions but are unlikely to affect immediate stock price.
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Jamie Constantine
Investor Relations
+1 781 873 2402
SOURCE Alkermes plc